Protagonist Therapeutics, Inc. (PTGX)
147.75
+3.42
(+2.37%)
USD |
NASDAQ |
Aug 31, 16:00
147.00
-0.75
(-0.51%)
After-Hours: 06:57
Protagonist Therapeutics Free Cash Flow : 130.58M for June 30, 2026
Free Cash Flow Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Free Cash Flow Data
| Date | Value |
|---|---|
| June 30, 2026 | 130.58M |
| March 31, 2026 | -117.90M |
| December 31, 2025 | 56.08M |
| September 30, 2025 | 63.71M |
| June 30, 2025 | 37.10M |
| March 31, 2025 | 335.29M |
| December 31, 2024 | 182.80M |
| September 30, 2024 | 229.23M |
| June 30, 2024 | 230.85M |
| March 31, 2024 | -64.16M |
| December 31, 2023 | -70.84M |
| September 30, 2023 | -119.49M |
| June 30, 2023 | -117.84M |
| March 31, 2023 | -105.35M |
| December 31, 2022 | -108.93M |
| September 30, 2022 | -104.36M |
| June 30, 2022 | -107.73M |
| March 31, 2022 | -118.01M |
| December 31, 2021 | -108.97M |
| September 30, 2021 | -100.82M |
| Date | Value |
|---|---|
| June 30, 2021 | -88.46M |
| March 31, 2021 | -85.88M |
| December 31, 2020 | -72.97M |
| September 30, 2020 | -68.48M |
| June 30, 2020 | -66.04M |
| March 31, 2020 | -41.65M |
| December 31, 2019 | -42.49M |
| September 30, 2019 | -38.18M |
| June 30, 2019 | -33.67M |
| March 31, 2019 | -51.92M |
| December 31, 2018 | -50.43M |
| September 30, 2018 | -54.44M |
| June 30, 2018 | -4.503M |
| March 31, 2018 | -1.736M |
| December 31, 2017 | 3.206M |
| September 30, 2017 | 7.679M |
| June 30, 2017 | -39.86M |
| March 31, 2017 | -35.26M |
| December 31, 2016 | -30.35M |
Free Cash Flow Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Free Cash Flow Benchmarks
| AbbVie, Inc. | 18.21B |
| Gilead Sciences, Inc. | 12.94B |
| Johnson & Johnson | 22.61B |
| Alnylam Pharmaceuticals, Inc. | 793.94M |
| BioMarin Pharmaceutical, Inc. | 725.08M |
Free Cash Flow Related Metrics
| Cash from Operations (Quarterly) | 219.05M |
| Cash from Investing (Quarterly) | -2.43M |
| Cash from Financing (Quarterly) | 9.743M |
| Free Cash Flow Per Share (Quarterly) | 3.083 |
| Free Cash Flow to Equity (Quarterly) | 219.44M |
| Free Cash Flow to Firm (Quarterly) | 218.88M |
| Free Cash Flow Yield | 1.31% |